Article: Cerulean gets $10m for nanoparticles.(Tuesday, July 28)

A month after an in-licensing deal allowed it to jump ahead into clinical development with a nanoparticle drug candidate, Cerulean Pharma Inc. pulled in $10 million in a Series B-1 financing to push that program forward and advance its platform technologies. That adds about one year of cash to the Cambridge, Mass.-based company, which has raised about $32 million to date since it was founded in late 2006 as Tempo Pharmaceuticals with the aim of developing nanoparticles able to effect the temporal release of drugs exclusively to diseased tissue. Late last month, Cerulean picked up ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!